Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
15 March 2022
| COVID-19: Vaccines
Overview
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updated: version 15 March 2022.
For translations of this document in other languages, click here.
Related links:
- Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: Grading of evidence, Evidence to recommendation tables
- Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: Background document to the WHO Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
Archived versions:
- Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac - Version 24 May 2021
- Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac - Version 21 October 2021
WHO Team
Agenda, Policy & Strategy (APS),
Immunization, Vaccines and Biologicals (IVB),
Strategic Advisory Group of Experts on Immunization,
WHO Headquarters (HQ)
Number of pages
8
Reference numbers
WHO Reference Number: WHO/2019-nCoV/vaccines/SAGE_recommendation/Sinovac-CoronaVac/2021.2
Copyright
